Aridis Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. Co.'s product candidates include: AR-301, which is a fully human immunoglobulin 1 (IgG1) mAb targeting the gram-positive bacteria Staphylococcus aureus alphatoxin; AR-105, which is a fully human IgG1 mAb targeting the gram-negative bacteria Pseudomonas aeruginosa; AR-101, which is a fully human immunoglobulin M mAb targeting the gram-negative bacteria P. aeruginosa serotype O11; and AR-401, which is its mAb discovery program aimed at treating infections caused by Acinetobacter baumannii. The ARDS stock yearly return is shown above.
The yearly return on the ARDS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARDS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|